Proteomics International, a contract research organisation and proteomics laboratory based in Perth, Australia, has signed a collaborative agreement with inVentiv Health Clinical to offer developers of biosimilar medicines outsourced services that “seamlessly transition from characterisation to clinical trials”.
Formerly known as PharmaNet/i3, inVentiv Health Clinical is the clinical-research arm of inVentiv Health, the US-headquartered provider of clinical development, commercialisation and consulting services.
In its partnership with Proteomics International, inVentiv will bring an array of bioanalytical capabilities to the biosimilars development process, from all phases of clinical trials through to commercialisation.
For its part, Proteomics International will apply advanced instrumentation to the structural characterisation and quality-control testing of proposed and referenced products in the initial stages of biosimilars and biologics development.
The collaboration with inVentiv is “a significant opportunity for us in furthering expansion into biogeneric markets”, noted Dr Richard Lipscombe, managing director of Proteomics International.
Dr George Scott, vice president, bioanalytical services at inVentiv Clinical, highlighted Proteomic International’s strengths in demonstrating biosimilarity, combined with his own company’s clinical, commercial and consulting expertise in biologics.
“Together we offer the full breadth and scope of an integrated roadmap of biosimilar development services to help navigate the complex regulatory and development landscape from early strategic planning, clinical trial conduct and registration to commercialisation,” Scott added.